Stem cell transplantation : biology, processing, and therapy
著者
書誌事項
Stem cell transplantation : biology, processing, and therapy
Wiley-VCH, c2006
- alk. paper
大学図書館所蔵 全2件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
This is the first handbook on the whole field of stem cell research covering (1) molecular and cellular fundamentals, (2) clinical applications and (3) GMP processing. It provides a timely overview of the potential and plasticity of adult stem cells. With its focus on standardization and quality control of cell lines suited for processing and clinical trials, the book features novel therapeutic approaches that offer great promise for new ways of treating neural, hematological and cardiovascular diseases. The editors are leading international experts in adult stem cell research, and their successful networking in the US and Europe has resulted in a distinguished team of authors from around the world.
目次
Preface. List of Contributors. Part I Stem Cell Biology. 1 Clinical Potentials of Stem Cells: Hype or Hope? (Anthony D. Ho and Wolfgang Wagner). 1.1 Introduction. 1.2 What are Stem Cells? 1.3 Stem Cells and Regeneration. 1.4 Adult and Embryonic Stem Cells. 1.5 In the Beginning was the Hematopoietic Stem Cell. 1.6 Trans-Differentiation of ASCs. 1.7 The Plasticity of ASCs: All Hype and no Hope? 1.8 The Battle of Two Cultures: ESCs versus ASCs. 1.9 The Challenges for Stem Cell Technology. 1.10 Regulation of Self-Renewal versus Differentiation, Asymmetric Divisions. 1.11 Genotype and Expression Profiles of Primitive HSCs. 1.12 Maintaining Stemness: Interactions between HSCs and the Cellular Microenvironment. 1.13 Mesenchymal Stem Cells. 1.14 Preliminary Clinical Studies. 1.15 Concluding Remarks and Future Perspectives. 2 Alteration of Hematopoietic Stem Cell Fates by Chromatin-Modifying Agents (Nadim Mahmud, Mohammed Milhem, Hiroto Araki, and Ronald Hoffman). 2.1 Introduction. 2.2 Cytotoxicity/Antitumor Activity versus Hypomethylating Effects of 5-Azacytidine and its Analogues. 2.3 Treating HSC with 5azaD/TSA can Alter their Fate. 2.4 Are the Effects of 5azaD/TSA Due to Cytotoxicity? 2.5 Treating HSC with Valproic Acid. 2.6 Ex-vivo Expansion of HSC Using Chromatin-Modifying Agents. 2.7 Reactivation of Gene Expression by Treating Cells with Chromatin-Modifying Agents. 2.8 Alteration of Nonhematopoietic Fate by Chromatin-Modifying Agents. 2.9 Safety/Toxicity of Treating Cells with Chromatin-Modifying Agents. 2.10 Conclusion. 3 Increasing Impact of Micro RNAs in Stem Cell Biology and Medicine (Peter Wernet). 3.1 Introduction. 3.2 Biogenesis of miRNAs. 3.3 Action Modes of miRNAs. 3.4 Potential Function Modes of miRNAs. 3.5 Conclusions. Part II Standardization and Quality Assurance of Stem Cell Preparations. 4 Novel Strategies for the Mobilization of Hematopoietic Stem Cells (Stefan Fruehauf, Timon Seeger, and Julian Topaly). 4.1 Physiology of Blood Stem Cell Mobilization. 4.2 Innovative Agents for PBPC Mobilization. 5 Pluripotent Stem Cells from Umbilical Cord Blood (Gesine Kogler and Peter Wernet). 5.1 Biological Advantages of Cord Blood as a Stem Cell Resource. 5.2 The Generation and Expansion of Pluripotent Cells (USSC) from Cord Blood. 5.3 Other Multipotent Nonhematopoietic Stem Cells: Mesenchymal Cells in CB and CB Tissue. 5.4 Conclusion: Future Efforts Towards the Regenerative Capacity of CB Nonhematopoietic Cells. 6 Good Manufacturing Practices: Clinical-Scale Production of Mesenchymal Stem Cells (Luc Sensebe, Philippe Bourin, and Luc Douay). 6.1 Introduction. 6.2 Prerequisites for the Clinical-Scale Production of MSCs. 6.3 Clinical-Scale Production: the French Experience. 6.4 QA and QC. 6.5 Future Prospects. 7 The Clonal Activity of Marked Hematopoietic Stem Cells (Jingqiong Hu, Manfred Schmidt, Annette Deichmann, Hanno Glimm, and Christof von Kalle). 7.1 Introduction. 7.2 Characterization of In-vivo Clonal Activity of HSCs by Genetic Marking. 7.3 Retroviral Integration Site Analysis. 7.4 Clonality Analysis in Animal Model and Human Gene Therapy Trials. 7.5 Interaction of Retroviral Integration Site and Transgene Expression with Clonal Activity of the Respective HSC. 7.6 Clinical Interventions Affect the Clonal Activity of Marked HSCs. 7.7 Perspectives. Part III On the Threshold to Clinical Applications. 8 ALarge Animal Non-Injury Model for Study of Human Stem Cell Plasticity (Graca Almeida-Porada, Christopher D. Porada, and Esmail D. Zanjani). 8.1 Introduction. 8.2 The Uniqueness of the Fetal Sheep Model. 8.3 Differentiative Potential of Human Cells in the Fetal Sheep Model. 9 Developmental Potential of Somatic Stem Cells Following Injection into Murine Blastocysts (Michael Durr, Friedrich Harder, and Albrecht M. Muller). 9.1 Introduction. 9.2 Neurosphere Cells Generate Erythroid-Like Cells Following Injection into Early Embryos. 9.3 Hematopoietic Chimerism by Human Cord Blood-Derived HSCs. 9.4 Injection of Leukemic Cells into Blastocysts. 9.5 Discussion. 10 Testing the Limits: The Potential of MAPC in Animal Models (Felipe Prosper and Catherine M. Verfaillie). 10.1 Introduction. 10.2 Characterization of MAPCs. 10.3 In-Vitro Differentiation Potential of MAPCs. 10.4 In-Vivo Differentiation Potential of MAPCs. 10.5 Mechanisms Underlying the Phenomenon of MAPCs. 10.6 Conclusion. 11 Mesenchymal Stem Cells as Vehicles for Genetic Targeting of Tumors (Frank Marini, Brett Hall, Jennifer Dembinski, Matus Studeny, A. Kate Sasser, and Michael Andreeff). 11.1 Introduction. 11.2 The Tumor Stroma and its Components. 11.3 The Role of Tumor-Stroma Interactions in Tumor Progression. 11.4 The Similarity of MSC Tumor Tropism to Wound Healing. 11.5 The Rationale for using MSCs as Cellular Delivery Vehicles. 11.6 The Challenges in Developing MSC-Based Delivery Strategies. 11.7 Conclusions. Part IV Clinical Trials. 12 Endothelial Progenitor Cells for Cardiac Regeneration (Ulrich Fischer-Rasokat and Stefanie Dimmeler). 12.1 Characterization of Endothelial Progenitor Cells. 12.2 Functions of EPCs to Improve Cardiac Function. 12.3 Mechanisms of Homing. 12.4 Results from Clinical Studies.6 13 Stem Cells and Bypass Grafting for Myocardial and Vascular Regeneration (Christof Stamm, Dirk Strunk, and Gustav Steinhoff). 13.1 Introduction. 13.2 Coronary Artery Disease. 13.3 Indications for CABG Surgery. 13.4 The Rationale for Cell Therapy in CABG Patients. 13.5 The Role of Bone Marrow Cells. 13.6 Combination of (Stem) Cell Treatment with CABG Surgery. 13.7 Outlook. 14 Adoptive Immunotherapy: Guidelines and Clinical Practice (Hans-Jochem Kolb, Christoph Schmid, Iris Bigalke, Raymund Buhmann, Belinda Simoes, Ting Yang, Johanna Tischer, Michael Stanglmaier, Horst Lindhofer, Christine Falk, and Georg Ledderose). 14.1 Introduction. 14.2 Animal Experiments. 14.3 The First Clinical Results in CML. 14.4 The EBMT Study. 14.5 The Graft-versus-Leukemia Effect. 14.6 Cytokines. 14.7 Bispecific Antibodies. 14.8 NK and NK-T Cells and HLA-Haploidentical Transplantation. 14.9 Outlook of Adoptive Immunotherapy in Chimerism. 15 Immune Escape and Suppression by Human Mesenchymal Stem Cells (Katarina Le Blanc and Olle Ringden). 15.1 Introduction. 15.2 MSCs Escape the Immune System. 15.3 Immunosuppression by MSCs. 15.4 MSC in the Clinic. 16 Stem Cell Transplantation: The Basis for Successful Cellular Immunotherapy (Peter Dreger, Matthias Ritgen, and Anthony D. Ho). 16.1 Introduction. 16.2 Allogeneic Stem Cell Transplantation in CLL. 16.3 Graft-versus-Leukemia Effect in CLL. 16.4 Allo-SCT with Reduced-Intensity Conditioning in CLL. 16.5 RICT from Unrelated Donors. 16.6 T-Cell Depletion. 16.7 Allo-SCT in Follicular Lymphoma. 16.8 Allo-SCT in Waldenstrom's Disease. 16.9 Conclusions and Perspectives. Index.
「Nielsen BookData」 より